Lippincott, Williams & Wilkins:530 Walnut Street:Philadelphia, PA 19106:(800)638-3030, (301)223-2300, EMAIL: [email protected], INTERNET: http://www.lww.com, Fax: (301)223-2320, (301)223-2320
Abstract
The aim of the current study was to assess the ability of amlodipine to dilate the coronary vessels in subjects with angiographically normal coronary arteries and normal left ventricular function. Ten patients, six women and four men (mean age 48 +/- 14 years, range 25-67 years) were enrolled. Coronary flow velocity and coronary perfusion pressure were invasively measured at baseline, during intracoronary adenosine (1-mg bolus) and at 5, 15, and 30 min following IV amlodipine (10 or 20 mg). Quantitative coronary angiography was performed at baseline and at 5, 15, and 30 min after amlodipine. Coronary cross-sectional area and mean coronary flow velocity progressively increased after amlodipine administration, resulting in an average increase in coronary flow at 30 min of 76%. On an individual basis, all patients but one showed a consistent trend toward a progressive coronary vasodilator effect of amlodipine over time. The peak effect of amlodipine on baseline mean coronary flow velocity was 43 +/- 12% that of adenosine. This is the first clinical study demonstrating that the IV administration of amlodipine produces a powerful coronary vasodilatation in subjects with angiographically normal coronary arteries and normal ventricular function, besides its known systemic vasodilating effects. The coronary vasodilating properties of amlodipine are particularly expressed at the microcirculatory level
